Guangzhou Boteng Biomedical Technology

Guangzhou Boteng Biomedical Technology was a China-based biomedical drug research company focused on pharmaceutical R&D and biotechnology development services. The company appears to have operated as a wholly owned subsidiary of Hefei Institute of Pharmaceutical Industry and was registered in Guangzhou in 2012. Publicly indexed pipeline records associate it with clinical development of small-molecule cardiovascular and neurology assets including piragrel sodium injection and HY-021068, primarily for ischemic stroke. Chinese corporate registry sources indicate the company was formally deregistered on December 18, 2020, so it is no longer an active operating entity despite some pipeline databases continuing to link historical trials to it.